Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study

INTRODUCTION: Ischaemic heart disease (IHD) is one of the most common causes of death in the UK and treatment of patients with IHD costs the National Health System (NHS) billions of pounds each year. Allopurinol is a xanthine oxidase inhibitor used to prevent gout that also has several positive effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackenzie, Isla S, Ford, Ian, Walker, Andrew, Hawkey, Chris, Begg, Alan, Avery, Anthony, Taggar, Jaspal, Wei, Li, Struthers, Allan D, MacDonald, Thomas M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020706/
https://www.ncbi.nlm.nih.gov/pubmed/27609859
http://dx.doi.org/10.1136/bmjopen-2016-013774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020706/
https://www.ncbi.nlm.nih.gov/pubmed/27609859
http://dx.doi.org/10.1136/bmjopen-2016-013774

Ejemplares similares